Lilly pips rival in Aussie obesity pill race
Eli Lilly has pipped Novo Nordisk in the race to launch the first oral GLP-1 drug in Australia, with Foundayo to be launched in the “coming days”, for both weight management and type 2 diabetes, at a more competitive price.
To see the whole article, log in or create an account.